Your browser doesn't support javascript.
loading
Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.
Liu, Chunxiao; Zha, Zhengyu; Zhou, Chenhao; Chen, Yeh; Xia, Weiya; Wang, Ying-Nai; Lee, Heng-Huan; Yin, Yirui; Yan, Meisi; Chang, Chiung-Wen; Chan, Li-Chuan; Qiu, Yufan; Li, Hui; Li, Chia-Wei; Hsu, Jung-Mao; Hsu, Jennifer L; Wang, Shao-Chun; Ren, Ning; Hung, Mien-Chie.
Affiliation
  • Liu C; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zha Z; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhou C; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, C
  • Chen Y; Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan.
  • Xia W; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang YN; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee HH; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yin Y; Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.
  • Yan M; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Pathology, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
  • Chang CW; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chan LC; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Qiu Y; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinica
  • Li H; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, C
  • Li CW; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hsu JM; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan.
  • Hsu JL; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang SC; Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan.
  • Ren N; Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China. Electronic address: ren.ning@zs-hospital.sh.cn.
  • Hung MC; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan. Electronic address: mh
J Hepatol ; 74(4): 907-918, 2021 04.
Article in En | MEDLINE | ID: mdl-33031845
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ribonucleases / Protein-Tyrosine Kinases / Proto-Oncogene Proteins / Receptor Protein-Tyrosine Kinases / Carcinoma, Hepatocellular / Protein Kinase Inhibitors / Carcinogenesis / Crizotinib / Liver Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2021 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ribonucleases / Protein-Tyrosine Kinases / Proto-Oncogene Proteins / Receptor Protein-Tyrosine Kinases / Carcinoma, Hepatocellular / Protein Kinase Inhibitors / Carcinogenesis / Crizotinib / Liver Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2021 Type: Article Affiliation country: United States